Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Can Fite Biopharma's Enterprise Value is $-1.31 Mil.
Can Fite Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.95 Mil. Therefore, Can Fite Biopharma's EV-to-OCF for today is 0.15.
The historical rank and industry rank for Can Fite Biopharma's EV-to-OCF or its related term are showing as below:
CANF'
s EV-to-OCF Range Over the Past 10 Years
Min: -6.43 Med: -0.43 Max: 0.66
Current: 0.15
During the past 13 years, the highest EV-to-OCF of Can Fite Biopharma was 0.66. The lowest was -6.43. And the median was -0.43.
CANF's EV-to-OCF is ranked worse than 72.86% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs CANF: 0.15
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Can Fite Biopharma (AMEX:CANF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Can Fite Biopharma's PE Ratio (TTM) for today is calculated as:
Can Fite Biopharma's share price for today is $3.21.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.782.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Can Fite Biopharma EV-to-OCF Related Terms
Can Fite Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's EV-to-OCF falls into.
Can Fite Biopharma's current Enterprise Value is $-1.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a EV-to-OCF of 0.15 as of Jul. 23, 2026. According to the industry distribution chart, Can Fite Biopharma ranks #1028 out of 1411 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Can Fite Biopharma's EV-to-OCF too high?
Can Fite Biopharma's current EV-to-OCF is 0.15. Based on the distribution chart, Can Fite Biopharma ranks #1028 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #1028 out of 1411 companies for EV-to-OCF. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Can Fite Biopharma's current EV-to-OCF is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.89, compared to a current price of $3.21 — trading 45.5% below its estimated fair value. The current EV-to-OCF is 0.15. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current EV-to-OCF is 0.15 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.21 is trading 45.5% below its estimated GF Value™ of $5.89.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
EV-to-OCF: 0.15
GF Value™: $5.89 vs. price of $3.21 (45.5% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
